Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism

Psychiatry Research

Volumn 175, Issue 1-2, 2010, Pages 47-53

  Kale, Anvita ^a   Naphade, Nilesh ^b   Sapkale, Swati ^b   Kamaraju, Marellasv ^b   Pillai, Anilkumar ^c   Joshi, Sadhana ^a   Mahadik, Sahebarao ^c  

^a Bharati Vidyapeeth Deemed University   (India)

^b Bharati Vidyapeeth's Medical College   (India)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cortisol; Docosahexaenoic acid; Folic acid; Homocysteine; Schizophrenia; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FOLIC ACID; HOMOCYSTEINE; HYDROCORTISONE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARBON METABOLISM; CONTROLLED STUDY; DIET; ERYTHROCYTE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RACE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DOCOSAHEXAENOIC ACIDS; ERYTHROCYTES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYDROCORTISONE; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; VITAMIN B 12; YOUNG ADULT;

EID: 72049102379     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.01.013     Document Type: Article

References (75)

1. Abdolmaleky H.M., Cheng K.H., Russo A., Smith C.L., Faraone S.V., Wilcox M., Shafa R., Glatt S.J., Nguyen G., Ponte J.F., Thiagalingam S., and Tsuang M.T. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 134 (2005) 60-66
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (1994), American Psychiatric Press., Washington, DC
3. Applebaum J., Shimon H., Sela B.A., Belmaker R.H., and Levine J. Homocysteine levels in newly admitted schizophrenic patients. Journal of Psychiatric Research 38 (2004) 413-416
4. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., and Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 53 (2003) 56-64
5. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., and Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 62 (2003) 195-204
6. Assies J., Lieverse R., Vreken P., Wanders R.J., Dingemans P.M., and Linszen D.H. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biological Psychiatry 49 (2001) 510-522
7. Boldyrev A.A., and Johnson P. Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. Journal of Alzheimer's Disease 11 (2007) 219-228
8. Bromberg A., Levine J., Nemetz B., Belmaker R.H., and Agam G. No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophrenia Research 101 1-3 (2008) 50-57
9. Brown A.S., Bottiglieri T., Schaefer C.A., Quesenberry Jr. C.P., Liu L., Bresnahan M., and Susser E.S. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Archives of General Psychiatry 64 1 (2007) 31-39
10. Buckley P.F., Pillai A., Evans D., Stirewalt E., and Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophrenia Research 91 (2007) 1-5
11. Chen H., Zhang M.S., Schwarzschild A.M., Heran A.M., Logroscino G., Willet C.W., and Ascherio A. Folate intake and risk of Parkinson's disease. American Journal of Epidemiology 160 (2004) 368-375
12. 12. Psychopharmacology 19 (2005) 59-65
13. Devlin A.M., Ling E.H., Peerson J.M., Clarke R., Smith A.D., and Halsted C.H. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Human Molecular Genetics 9 (2000) 2837-2844
14. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., and Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukotrienes and Essential Fatty Acids 69 (2003) 393-399
15. Frankenburg F.R. The role of one-carbon metabolism in schizophrenia and depression. Harvard Revews in Psychiatry 15 (2007) 146-160
16. Goff D.C., Bottiglieri T., Arning E., Shih V., Freudenreich O., Evins A.E., Henderson D.C., Baer L., and Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. American Journal of Psychiatry 161 (2004) 1705-1708
17. Gopalan C., Rama Sastri B.V., and Balasubramanian S.C. Nutritive Value of Indian Books (1996), National Institute of Nutrition, Indian Council of Medical Research, Hyderabad
18. Haidemenos A., Kontis D., Gazi A., Kallai E., Allin M., and Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Progress in Neuro-psychopharmacology and Biological Psychiatry 31 (2007) 1289-1296
19. Herran A., Garcia-Unzueta M.T., Amado J.A., Lopez-Cordovilla J.J., Diez-Manrique J.F., and Vazquez-Barquero J.L. Folate levels in psychiatric outpatients. Psychiatry and Clinical Neuroscience 53 (1999) 531-533
20. Horrobin D.F., Manku M.S., Hillman H., Iain A., and Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry 30 (1991) 795-805
21. Jarskog L.F., Gilmore J.H., Selinger E.S., and Lieberman J.A. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry 48 (2000) 641-650
22. Kale A., Joshi S., Naphade N., Sapkale S., Raju M.S.V.K., Pillai A., Nasrallah H., and Mahadik S. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophrenia Research 98 (2008) 295-301
23. Kay S., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 (1987) 261-275
24. Kemperman R.F., Veurink M., van der Wal T., Knegtering H., Bruggeman R., Fokkema M.R., Kema I.P., Korf J., and Muskiet F.A. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukotrienes and Essential Fatty Acids 74 (2006) 75-85
25. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 58 (2002) 1-10
26. Kohen F., Pazzagli M., Kim J.B., and Lindner H.R. An immunoassay for plasma cortisol based on chemiluminescence. Steroids 36 (1980) 421-437
27. Krøll J. Schizophrenia and liver dysfunction. Medical Hypotheses 56 (2001) 634-636
28. Krøll J. Schizophrenia and Liver Dysfunction Caused by Portacaval Shunting. Current Psychiatry Reviews 8 (2007) 205-212
29. 12 assay methods. A review. Clinical Biochemistry 18 (1985) 261-266
30. Levine J., Stahl Z., Sela B.A., Gavendo S., Ruderman V., and Belmaker R.H. Elevated homocysteine levels in young male patients with schizophrenia. American Journal of Psychiatry 159 (2002) 1790-1792
31. Levine J., Stahl Z., Sela B.A., Ruderman V., Shumaico O., Babushkin I., Osher Y., Bersudsky Y., and Belmaker R.H. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biological Psychiatry 60 3 (2006) 265-269
32. Lipton S.A., Kim W.K., Choi Y.B., Kumar S., D'Emilia D.M., Rayudu P.V., Arnelle D.R., and Stamler J.S. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proceedings of the National Academe of Science, USA 94 (1997) 5923-5928
33. Mahadik S.P., and Yao J.K. Phospholipids in schizophrenia. In: Lieberman J.A., Stroup T.S., and Perkins D.O. (Eds). Textbook of Schizophrenia (2006), American Psychiatric Publishing, Washington, DC 117-135
34. Mahadik S.P., Sitasawad V., and Mulchandani M. Membrane peroxidation and the neuropathology of schizophrenia. In: Peet M., Glen I., and Horrobin D. (Eds). Phospholipid Spectrum Disorders in Psychiatry (1999), Marius Press, Lancashire, UK 99-111
35. Mahadik S.P., Mulchandani M., Hegde M.V., and Ranjekar P.K. Cultural and socioeconomic differences in dietary intake of essential fatty acids and antioxidants: effects on the outcome. In: Horrobin D., Glen A.L., and Peet M. (Eds). Phospholipid Spectrum Psychiatric Disorders (1999), Marius Press, Carnforth, UK 167-179
36. Mahadik S.P., Evans D., and Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Progress in Neuro-psychopharmacology and Biological Psychiatry 25 (2001) 463-493
37. Manku M.S., Horrobin D.F., Huang S., and Morse N. Fatty acids in plasma and red cell membranes. Lipids 18 (1983) 906-908
38. Mattson M.P., and Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in Neuroscience 26 (2003) 137-146
39. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., and Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophrenia Research 91 (2007) 37-50
40. Monji A., Yanagimoto K., Maekawa T., Sumida Y., Yamazaki K., and Kojima K. Plasma folate and homocysteine levels may be related to interictal "schizophrenia-like" psychosis in patients with epilepsy. Journal of Clinical Psychopharmacology 25 (2005) 3-5
41. Muntjewerff J.W., and Blom H.J. Aberrant folate status in schizophrenic patients: what is the evidence?. Progress in Neuro-psychopharmacology and Biological Psychiatry 29 (2005) 1133-1139
42. Muntjewerff J.W., van der Put N., Eskes T., Ellenbroek B., Steegers E., Blom H., and Zitman F. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Research 121 (2003) 1-9
43. Muntjewerff J.-W., Gellekink H., den Heijer M., Hoogendoorn M.L.C., Kahn R.S., Sinke R.J., and Blom H.J. Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia. Progress in Neuro-psychopharmacol Biological Psychiatry 18 (2008) 99-106
44. Osmond H., and Smythies J. Schizophrenia: a new approach. Journal of Mental Science 98 (1952) 309-314
45. Picker J.D., and Coyle J.T. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia?. Harvard Reviews in Psychiatry 13 (2005) 197-205
46. Pita M.L., and Delgado M.J. Folate administration increases n-3 polyunsaturated fatty acids in rat plasma and tissue lipids. Thrombosis and Haemostasis 84 (2000) 420-423
47. Raju MSVK., Naphade N., Joshi S., Kale A., Sapkale S., and Mahadik S.P. Hippocampal volume deficits in first episode schizophrenia: relationship to symptoms and membrane EPUFA levels. 62nd Annual Meeting of the Society of Biological Psychiatry 61 (2007) 257S
48. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., and Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 121 (2003) 109-122
49. Rao S., Joshi S., Kale A., Hegde M., and Mahadik S. Maternal folic acid supplementation to dams on marginal protein level alters brain fatty acid levels of their adult offspring. Metabolism: Clinical and Experimental 55 (2006) 628-634
50. Regland B. Schizophrenia and single-carbon metabolism. Progress in Neuro-psychopharmacology and Biological Psychiatry 29 (2005) 1124-1132
51. Reif A., Pfuhlmann B., and Lesch K.P. Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Progress in Neuro-psychopharmacol Biological Psychiatry 29 (2005) 1162-1168
52. Roffman J.L., Weiss A.P., Purcell S., Caffalette C.A., Freudenreich O., Henderson D.C., Bottiglieri T., Wong D.H., Halsted C.H., and Goff D.C. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biological Psychiatry 63 (2008) 42-48
53. Sachdev P., Loo C., Mitchell P., and Malhi G. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry and Clinical Neuroscience 59 (2005) 354-357
54. Sharma R.P. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophrenia Research 72 (2005) 79-90
55. Shoval G., and Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. European Neuropsychopharmacology 15 (2005) 319-329
56. Silver H. Vitamin B12 levels are low in hospitalized psychiatric patients. Israeli Journal of of Psychiatry and Related Sciences 37 (2000) 41-45
57. Simopoulos A.P. Highlights of the National Institutes of Health Program in Biomedical and Behavioral Nutrition and Research Training-with the emphasis on total parenteral and enteral nutrition. American Journal of Clinical Nutrition 34 (1981) 1187-1190
58. Skerritt U.M. A prevalence study of folate deficiency in a psychiatric in-patient population. Acta Psychiatrica Scandinavica 97 (1998) 228-232
59. Smythies J.R. Recent advances in the biochemistry of schizophrenia. Guy's Gazette 14 (1966) 2-7
60. Smythies J.R. The transmethylation and one-carbon cycle hypotheses of schizophrenia. Psychological Medicine 13 (1983) 711-714
61. Smythies J.R., Gottfries C.G., and Regland B. Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Biological Psychiatry 41 (1997) 230-233
62. Srinivasan L., and Tirupati S. Relationship between cognition and work functioning among patients with schizophrenia in an urban area of India. Psychiatric Services 56 (2005) 1423-1428
63. Stahl Z., Belmaker R.H., Friger M., and Levine J. Nutritional and life style determinants of plasma homocysteine in schizophrenia patients. European Neuropsychopharmacology 15 (2005) 291-295
64. Susser E., Brown A.S., Klonowski E., Allen R.H., and Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: a possible association. Biological Psychiatry 44 (1998) 141-143
65. Thara R. Twenty-year course of schizophrenia: the Madras Longitudinal Study. Canadian Journal of Psychiatry 49 (2004) 564-569
66. Tunbridge E.M., Harrison P.J., Warden D.R., Johnston C., Refsum H., and Smith A.D. Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 147 (2008) 996-999
67. Umhau J.C., Dauphinais K.M., Patel S.H., Nahrwold D.A., Hibbeln J.R., Rawlings R.R., and George D.T. The relationship between folate and docosahexaenoic acid in men. European Journal of Clinical Nutrition 60 (2005) 352-357
68. Vaskinn A., Sundet K., Friis S., Simonsen C., Birkenaes A.B., Engh J.A., Jónsdóttir H., Ringen P.A., Opjordsmoen S., and Andreassen O.A. The effect of gender on emotion perception in schizophrenia and bipolar disorder. Acta Psychiatrica Scandinavica 116 (2007) 263-270
69. Wainwright P.E. Do essential fatty acids play a role in brain and behavioral development?. Neuroscience and Biobehavoral Reviews 16 (1992) 193-205
70. Walder D.J., Walker E.F., and Levine R.J. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biological Psychiatry 48 (2000) 1221-1231
71. Wechsler D. Wechsler Adult Intelligence Scale Revised (1981), Psychological Corporation, New York, NY
72. Yao J.K., Reddy R.D., and van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15 (2001) 287-310
73. Yao J.K., Stanley J.A., Reddy R.D., Keshavan M.S., and Pettegrew J.W. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipids metabolites. Biological Psychiatry 52 (2002) 823-830
74. Yilmaz N., Herken H., Cicek H.K., Celik A., Yürekli M., and Akyol O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Medical Principals and Practices 16 (2007) 137-141
75. Zighetti M.L., Chantarangkul V., Tripodi A., Mannucci P.M., and Cattaneo M. Determination of total homocysteine in plasma: comparison of the Abbott IMx immunoassay with high performance liquid chromatography. Haematologica 87 (2002) 89-94